The Eli Lilly, Pfizer and Sanofi-backed cancer therapy developer raised $150m despite reducing the number of shares in the IPO and floating beneath its range.

The underwriters for Karolinska Institute spinout Aprea Therapeutics have taken up the over-allotment option in full to boost proceeds to nearly $97.8m.

The underwriters for Praktikertjänst-backed Aprea Therapeutics have taken up the over-allotment option in full to boost proceeds to nearly $97.8m.

Panasonic, Mitsui Sumitomo and NEC all booked exits after Honda's R&D unit acquired connected driving assistant technology developer Drivemode.

Comcast NBCUniversal may have scored an exit at online women's lifestyle brand PopSugar, although the firm was reported to have sold back at least some of its shares in 2009.

Qorvo has purchased a portfolio company, radio frequency technology developer Cavendish Kinetics, which was spun out of Cambridge two decades ago.

Qorvo has purchased a portfolio company, radio frequency technology developer Cavendish, in a deal that will also allow Qualcomm Ventures to exit.

The AstraZeneca-backed cancer drug developer had hoped to raise up to $212m in a US flotation but is instead pulling back due to unfavourable market conditions.

Emtek is set to sell up to $55m of its shares in online real estate platform PropertyGuru in an Australian initial public offering that could bring in up to $257m in proceeds.

AstraZeneca spinoff Viela Bio has gone public in an offering that involved existing backers buying some $70m worth of stock, and its share price has since risen 21.7%.